We expect to provide a comprehensive view of the ‘CYP3A interactome’, clarifying a substantial portion of CYP3A variability. The goal is to identify the main genetic and non-genetic determinants of CYP3A enzyme activity, with clinical utility as biomarkers guiding drug therapy. The approaches used in this project are broadly applicable to any genes of interest, to dissect complex genomic architecture, gene regulatory networks and discover genetic biomarkers for personalized drug therapy or disease prevention.
Dr. Mushiroda’s team has developed a targeted next generation sequencing (NGS) panel of 100 pharmacogenes related to pharmacokinetics based on multiplex-PCR, which can analyze common and rare variants comprehensively and accurately, and thus will be effective for the identification of PGx biomarkers (https://doi.org/10.18632/oncotarget.25712).
Since his mission is implementation of PGx testing, his team conducts prospective clinical trials to demonstrate the clinical utility of genetic tests using the PGx biomarkers identified by their basic research. If successful, this will lead to use of the PGx biomarkers as in-vitro diagnostics under the health insurance system. Recently, they completed a prospective PGx clinical trial, GENCAT that showed clinical utility of HLA-A*31:01 screening for patients who needed treatment with an antiepileptic drug carbamazepine (https://jamanetwork.com/journals/jamaneurology/article-abstract/2676800).
To tackle the issue of PGx regionally, in 2012 RIKEN established the South East Asian Pharmacogenomics Research Network (SEAPharm) together with five other Asian countries (Korea, Indonesia, Malaysia, Taiwan, and Thailand). Membership has been steadily increasing, with Singapore joining in 2014, and Vietnam in 2016. Last year, SEAPharm accepted three newcomers, Nepal, Laos and the Philippines, on the team. The aim of the collaboration is to identify PGx biomarkers associated with adverse drug reactions, such as skin rash induced by anti-epileptics and antibiotics, and hepatic injury induced by anti-tuberculosis agents. In addition, a new project has been started, which involves targeted NGS of genomic DNA from 1,000 people from 10 countries to clarify the genetic diversity of drug-metabolizing enzymes and drug transporters in Southeast Asian populations.
His group consists of more than 35 staff members from graduate students to post-doctoral scientists, covering disciplines from wet and dry lab and public health genomics projects, all focusing on pharmacogenomics and personalized medicine. In particular, his research interests involve discovery work and clinical implementation of pharmacogenomics, focusing in particular in psychiatry but also cardiology and oncology, genomics of rare disorders and transcriptional regulation of human fetal globin genes. Moreover, George’s group is internationally recognized for its involvement in developing National/Ethnic Genetic databases to document the genetic heterogeneity in different populations worldwide and of genome informatics tools to translate genomic information into a clinically meaningful format. Also, George’s group has a keen interest in public health genomics to critically assess the impact of genomics to society and public health.
George has more than 200 publications in peer-reviewed scientific journals and textbooks, some of them in leading scientific journals, such as Nature Genetics, Nature Rev Genet, Nucleic Acids Res, Genes Dev. Also, he has co-edited the textbook “Molecular Diagnostics”, published by Academic Press, now in its 3rd edition, and several other international textbooks, while he is the editor of “Translational and Applied Genomics” book series. Furthermore, he serves as Associate Editor and member of the editorial board of several scientific journals, such as Human Mutation, Human Genetics, Human Genomics, Pharmacogenomics, etc and has been a member of several international boards and advisory and evaluation committees.
Apart from that, George is the main co-organizer of the Golden Helix Conferences, an international meeting series on Pharmacogenomics and Genomic Medicine. He has given numerous keynote and plenary lectures in international conferences as invited speaker and his research projects received funding from national and international funding agencies.
Within this network fundamental and clinical researchers closely collaborate in the field of individualised therapy development.
The U-PGx consortium addresses major challenges and obstacles for implementation of PGx testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx investigates if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. Our main goal is to improve the safety and efficacy of pharmacotherapy for every European patient by enabling clinical pharmacogenomics. Based on the findings of the U-PGx project we will formulate European strategies for improving clinical implementation of pharmacogenomics. This project is funded by the European Community’s Horizon 2020 Programme under grant agreement No. 668353.
Professor Innocenti serves as the Chair of the Gastrointestinal Solid Tumor Correlative Science Group in the Alliance for Clinical Trials in Oncology (previously, Cancer and Leukemia Group B). He is also the Translational Science Representative of the NCI Colon Task Force of the Gastrointestinal Steering Committee.
Professor Innocenti has published more than 150 peer-reviewed publications and book chapters in clinical pharmacology, pharmacogenomics, and oncology. Major findings from landmark studies and seminal discoveries have been reported in the Journal of Clinical Oncology, JAMA, Cell, Clinical Pharmacology and Therapeutics, Clinical Cancer Research, Nature Genetics and other noteworthy journals. He is the editor of five books in pharmacogenomics and oncology. Professor Innocenti sits on the editorial board of Clinical Pharmacology and Therapeutics, and Pharmacogenetics and Genomics, among other journals. He is the Associate Editor for Pharmacogenomics.
Professor Innocenti received the Leon I Goldberg Young Investigator Award from the American Society of Clinical Pharmacology and Therapeutics in 2012, as well as a Young Investigator Award from the Cancer Research Foundation in 2006. He has received the National Scientific Qualification as Full Professor of Pharmacology, Clinical Pharmacology, and Pharmacognosy from Italy in 2014. Professor Innocenti is frequently invited to speak internationally on the topics of precision medicine and genomics in oncology. He has organized several international symposia and meetings on genomic and translational medicine and has chaired the Oncology Section of the American Society of Clinical Pharmacology and Therapeutics.
Among Professor Innocenti’s exemplary achievements is the elucidation of the genetic basis of severe neutropenia in cancer patients treated with irinotecan, a poster child for pharmacogenetics. Dr. Innocenti is the co-inventor of the FDA-approved UGT1A1 genetic test for patients treated with irinotecan. As a result of this pioneering work, the labeling of irinotecan has since been revised.
Professor Innocenti’s NIH-funded program applies genomic technologies to discover novel determinants of efficacy and safety of cancer therapy. This research aims to achieve the goal of precision therapy in oncology through the selection of the most effective treatment regimen for any given patient.
PGRN Hub & the Featured Investigator